The Company

Aadi Bioscience, Inc. (Aadi), is a privately held biopharmaceutical company focused on development and commercialization of precision medicines targeted to rare genomic alteration-driven cancers. Aadi’s initial focus is on the development and commercialization of the albumin bound mTOR inhibitor, FYARROTM (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus, ABI-009), for cancers driven by mTOR pathway activation including advanced malignant PEComa (a rare type of sarcoma) and TSC1 or TSC2 alterations in a tumor agnostic setting. 

 

Aadi plans to continue its precision medicine approach through initiation of a registrational trial in tumor-agnostic TSC1 and TSC2 alterations.

Please check out Our Science and Pipeline for information about our work